GSK - GSK plc
After hours:
| Previous Close | 33.80 |
| Open | 33.95 |
| Bid | 34.00 x 1100 |
| Ask | 34.16 x 3200 |
| Day's Range | 33.88 - 34.25 |
| 52 Week Range | 28.47 - 44.75 |
| Volume | |
| Avg. Volume | 2,889,204 |
| Market Cap | 69.84B |
| Beta (5Y Monthly) | 0.28 |
| PE Ratio (TTM) | 12.49 |
| EPS (TTM) | 2.73 |
| Earnings Date | Feb 01, 2017 - Feb 06, 2017 |
| Forward Dividend & Yield | 1.39 (4.12%) |
| Ex-Dividend Date | May 18, 2023 |
| 1y Target Est | 40.00 |
Simply Wall St.Investors in GSK (LON:GSK) have unfortunately lost 19% over the last year
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While...
Business WireGSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US
PHILADELPHIA, June 01, 2023--GSK announces the COiMMUNITY Initiative to help achieve higher adult vaccination rates in the US
- Reuters
UPDATE 2-US FDA approves Pfizer's RSV vaccine
The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's respiratory syncytial virus (RSV) vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors. The approval comes less than a month after the FDA approved a similar shot by rival GSK Plc. Pfizer's vaccine was approved for people aged 60 and older, the company said, the same age group as GSK's shot. In a late-stage study, Pfizer's vaccine, to be sold under the brand name Abrysvo, was 67% effective among those aged 60 and older with two or more symptoms of RSV, and 85.7% against severe illness defined by three or more symptoms.
CNW GroupBiopharma company GSK grants $1 million to Halifax-based Canadian Center for Vaccinology (CCfV)
GSK announces a $1 million grant to strengthen the Canadian Center for Vaccinology (CCfV)'s position in the national infectious disease research landscape. The private funding will be a catalyst for growth of the Halifax-based centre, increasing employment opportunities and bolstering top-quality research and pandemic preparedness locally and nationally.
- Reuters
UPDATE 2-US FDA panel backs Pfizer's maternal RSV vaccine for protecting infants
Advisers to the U.S. Food and Drug Administration on Thursday backed the safety and effectiveness of Pfizer Inc's experimental respiratory syncytial virus (RSV) vaccine, boosting its chances of becoming the first available maternal shot to protect babies from the illness. The FDA's advisory committee voted unanimously that available data supported the vaccine's efficacy for giving the shot to women in their second or third trimesters of pregnancy to prevent lower respiratory tract infection and severe disease in infants up to 6 months of age. The expert panel voted 10-4 that the data also supports the safety of the vaccine for that patient population, paving the way for likely U.S. approval.
- Reuters
US FDA advisers to discuss Pfizer's maternal RSV vaccine
Advisers to the U.S. Food and Drug Administration on Thursday will discuss Pfizer Inc's experimental respiratory syncytial virus (RSV) vaccine intended to protect infants through six months of age when given to expectant mothers. An estimated 58,000 to 80,000 children under 5 years old are hospitalized due to RSV infection annually in the United States, according to government data. The agency's staff reviewers on Tuesday deemed the safety data for Pfizer's vaccine "generally favorable".
Business WireBELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
MONTREAL, May 16, 2023--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previousl
- Reuters
UPDATE 3-US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute
The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal of a lower court's ruling reinstating the jury award for U.K.-based GSK. The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug.
ReutersUS Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute
The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal of a lower court's ruling reinstating the jury award for U.K.-based GSK. The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug.
- Simply Wall St.
Interested In GSK's (LON:GSK) Upcoming UK£0.14 Dividend? You Have Four Days Left
GSK plc ( LON:GSK ) is about to trade ex-dividend in the next 4 days. The ex-dividend date is one business day before...
Yahoo Finance UKTrending tickers: GSK | THG | Beazley | Disney
The latest investor updates on stocks that are trending on Friday.
Yahoo Finance UKWall Street loses ground as FTSE 100 closes higher on UK economy growth
FTSE 100 closes the week higher as the UK economy returned to growth.
GlobeNewswireSpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
STAMFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that data from two collaborator-sponsored clinical studies evaluating nirogacestat, an investigational oral gamma secretase inhibitor, in combination with B-cell maturation agent (BCMA) therapies in patients with relapsed or refractory multiple my
Motley FoolThe FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer
Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) are two healthcare companies aiming to produce a vaccine for the respiratory syncytial virus (RSV). In trials, their vaccine candidates have been proving highly effective, and it may not be long before these COVID-19 vaccine makers are fighting for market share again -- this time in the RSV market. The Food and Drug Administration (FDA) recently approved an RSV vaccine, and it wasn't from either of these two companies.
GlobeNewswireSCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update
SCYNEXIS announced an exclusive license agreement with GSK plc (LSE/NYSE: GSK) for the global rights to develop and commercialize BREXAFEMME® (ibrexafungerp tablets). SCYNEXIS will receive an upfront payment from GSK of $90 million upon deal close with future performance-based milestone payments of up to $503 million and tiered royalties.SCYNEXIS ended Q1 with cash, cash equivalents and short-term investments of $54.8 million, and upon receipt of the upfront payment from GSK will have a projecte
- Simply Wall St.
GSK plc (LON:GSK) is favoured by institutional owners who hold 82% of the company
Key Insights Significantly high institutional ownership implies GSK's stock price is sensitive to their trading actions...
CNW Group$3 million joint investment by GSK and U of T to launch the GSK Chair in Vaccine Education and Practice-Oriented Tools
The University of Toronto (U of T) and biopharma company GSK are investing $3 million for the creation of a new chair that will enhance and develop vaccine education programs and practice tools for pharmacists and other health professionals. GSK is providing $2 million, while U of T's Leslie Dan Faculty of Pharmacy is pitching in $1 million.
Yahoo Finance VideoGSK’s vaccine against RSV wins FDA approval
Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss the FDA’s approval of GlaxoSmithKline’s (GSK) vaccine against RSV.
- Reuters
PRESS DIGEST- New York Times business news - May 4
The Federal Trade Commission (FTC) escalated its fight with the tech industry's biggest companies as it moved to impose what it called a "blanket prohibition" on the collection of young people's personal data by Meta Platforms Inc. - The U.S. Senate voted on Wednesday to reinstate tariffs on solar panels from Chinese companies in Southeast Asia that had been found to be coming into the United States in violation of trade rules.
Business WireUS FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
PHILADELPHIA, May 03, 2023--US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults
- Reuters
UPDATE 3-US FDA approves first RSV vaccine from GSK
The U.S. Food and Drug Administration has approved GSK Plc's respiratory syncytial virus (RSV) vaccine, the British drugmaker said on Wednesday, making it the first shot to be cleared for protection against a common respiratory disease that can be fatal for older people. The approval makes GSK, which has been neck-and-neck with Pfizer in RSV vaccine development, the first company to tap into a multi-billion-dollar market and also puts it ahead of rivals such as Moderna Inc and Bavarian Nordic. Credit Suisse analysts expect $2.5 billion in peak sales for GSK's RSV vaccine for older adults.
The TelegraphInvestors may be sceptical, but this unloved stock has much to offer – and a lowly valuation
Here is an unloved stock that offers a new group structure, the potential resolution of legal woes, the presence of an activist investor, a clear strategy, a building pipeline of vaccines and medicines – and all with a lowly valuation.
Yahoo FinancePfizer to shift focus to new products amid decline in COVID sales
Pfizer reported strong earnings for the first quarter of the year, despite a decrease in COVID product demand. However, investors are wary of the company's anticipated product launches this year.
Yahoo Finance VideoWhy the human genome could be health care’s holy grail
23andMe Co-founder & CEO Anne Wojcicki says we’ve only seen the tip of the iceberg for human genomics and DNA research. “Look at all the explosion of all these new technologies with gene therapy, with CRISPR (CRSP), with RNA technologies and understanding the human genome,” Wojcicki told Yahoo Finance at the Milken Global Conference in Beverly Hills, California. Wojcicki says she’s ‘disappointed’ in the lack of progress around genomics, despite having just crossed a significant milestone, 20 years since the first complete sequencing of the human genome. “I think part of the reason is that genetics tells you a lot about what you're at risk for and it doesn't necessarily financially pay to get you that preventative information and to intervene in that way versus just treating people once they have a disease.” The 23andMe (ME) CEO also says they are looking into building new partnerships with pharmaceutical giants once the company’s partnership with GlaxoSmithKline (GSK) ends in July. Interview Highlights: 1:29 How genetics can tell us more about human diversity 2:20 Why 23andMe CEO is ‘disappointed’ about genome adoption 5:00 Wojcicki on 23andMe partnership with pharma giant GSK 7:15 Genetics needs to be part of medical school training 8:26 What’s next for 23andMe
Yahoo Finance23andMe CEO: We see more opportunities in DNA partnerships
23 & Me CEO Anne Wojicki reveals the next key opportunity for her company.